Regulatory FDA taps prior knowledge to expedite cell and gene therapy development BioSpaceA year of significant policy change at the FDA brought momentum and scrutiny into the new year.Gene Therapy PlatformRead full story pharminent June 3, 2026 (Last updated: June 3, 2026) BioSpace A year of significant policy change at the FDA brought momentum and scrutiny into the new year. Gene Therapy Platform Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie receives EC approval for Aquipta to treat migraineNext: Travere beefs up rare kidney disease portfolio with up to $1.1B China deal Related Stories Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026 Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026
